Jianmin Pharmaceutical Group Co (SHSE:600976) Net Income From Continuing Operations : ¥379 Mil (TTM As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Jianmin Pharmaceutical Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jianmin Pharmaceutical Group Co's net income from continuing operations for the three months ended in Mar. 2025 was ¥111 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥379 Mil.

Jianmin Pharmaceutical Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Jianmin Pharmaceutical Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jianmin Pharmaceutical Group Co Net Income From Continuing Operations Chart

Jianmin Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

148.69

305.94

406.02

523.23

367.75

Jianmin Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															100.20	140.86	83.53	43.16	111.04

Jianmin Pharmaceutical Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥379 Mil.

Jianmin Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jianmin Pharmaceutical Group Co Ltd (SHSE:600976) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 484 Parrot Avenue, Hanyang District, Wuhan, CHN, 430052

Website

http://www.whjm.com

Jianmin Pharmaceutical Group Co Ltd is engaged in the manufacture and distribution of pharmaceutical products. It adheres to the core position of pediatric medicine, gynecological medicine, and special Chinese medicine, it offers products under Jianmin and Longmu brands.

Executives

Du Ming De	Director
He Qin	Director
Gao Kai	senior management
Wang Jun	senior management
Huang Zhi Jun	senior management
Pei Xue Jun	senior management
Bu Zhong Jiang	Director
Cheng Chao Yang	senior management
Xu Sheng	senior management
Hu Zhen Bo	senior management
Liu Qin Qiang	Director
Xiong Fu Liang	senior management
Liu Peng	senior management

Jianmin Pharmaceutical Group Co Headlines

No Headlines